The Study
Urolithin A activates mitophagy via the AMPK–mTOR axis and modulates the gut–ceramide axis to ameliorate cardiac remodeling in HFpEF
This study is like watching a video of a mouse getting better after taking a special supplement — we see the heart gets stronger and the gut changes, but we don’t know for sure if the supplement caused it or if something else did. We can't say it will work in people yet.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
This study tested a natural compound from berries and nuts called urolithin A in mice with a type of heart failure where the heart muscle gets stiff. It found that the compound helped the heart relax better by cleaning up damaged energy factories inside heart cells and reducing harmful fats from gut bacteria.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 554 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — improved heart relaxation means less shortness of breath and fatigue, which are major symptoms of this common heart failure type.
- 2E/A ratio (a measure of heart relaxation) improved from high to near-normal; heart muscle thickening and scarring decreased; mitochondrial energy output increased; harmful fat molecules (ceramides) dropped by up to 40%.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Experimental & Molecular Medicine
Year
2026
Authors
Hangyul Song, Chahyeon Yun, Yunju Choi, Wooju Jeong, Yumin Kim, Jaeyoung Kim, Ju-Yeon Lee, Dongryeol Ryu, Sang-Wook Park, Chang-Myung Oh
Related Content
Claims (6)
In mice with heart failure with preserved ejection fraction, Urolithin A alters gut bacteria to reduce levels of ceramide-producing species and lowers ceramide in the blood, which is linked to decreased lipotoxic stress.
In mice with a specific type of heart failure caused by a high-fat diet and impaired nitric oxide production, Urolithin A treatment is linked to better heart relaxation, smaller heart muscle size, and less scar tissue in the heart.
In mice with heart failure with preserved ejection fraction, urolithin A increases AMPK activity, reduces mTOR activity, restores mitophagy, and improves mitochondrial energy production in heart tissue.
Urolithin A decreases changes in gene activity associated with heart muscle cell scarring under conditions mimicking heart failure with preserved ejection fraction.
Urolithin A enhances mitochondrial structure and function in heart tissue of mice with heart failure with preserved ejection fraction, resulting in improved cristae integrity and higher maximal oxygen consumption.
Urolithin A increases the removal of damaged mitochondria and improves mitochondrial function in heart tissue, which reduces heart tissue damage.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.